UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading |
| Name of each exchange |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Conditions.
On August 8, 2024, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for the fiscal quarter ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.
This information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 7, 2024, the Company’s board of directors appointed Bryan McMichael, age 46, the Company’s current Interim Chief Financial Officer, Executive Vice President, Accounting, Corporate Controller, to serve as the Company’s Chief Financial Officer effective August 1, 2024. Mr. McMichael will continue to serve as the Company’s Principal Financial Officer and Principal Accounting Officer. Mr. McMichael previously served as the Company’s Interim Chief Financial Officer and Principal Financial Officer since December 2023. In addition, Mr. McMichael previously served as the Company’s Executive Vice President, Accounting, Corporate Controller and Principal Accounting Officer, since March 2023 and served as Senior Vice President, Accounting, Corporate Controller and Principal Accounting Officer since September 2022. Starting March 2021, Mr. McMichael held the role of Senior Vice President, Accounting and Corporate Controller at the Company. Prior to joining the Company, Mr. McMichael worked for Gilead Sciences, Inc. from May 2016 to March 2021 and most recently held the position of Executive Director, Assistant Controller. Immediately prior to joining Gilead Sciences, Inc., Mr. McMichael served in various roles at NetApp, Inc. and PricewaterhouseCoopers LLP in the United States and in Europe. Mr. McMichael is a Certified Public Accountant and holds a Bachelor of Science degree in Business Administration from San Diego State University.
There are currently no arrangements or understandings between Mr. McMichael and any other person pursuant to which Mr. McMichael was selected as an executive officer. There are no family relationships between Mr. McMichael and any director or other executive officer of the Company, or with any person nominated or chosen to become an officer or a director of the Company. The Company has had no transactions since the beginning of its last fiscal year, and has no transactions currently proposed, in which Mr. McMichael, or any member of his immediate family, has an interest requiring disclosure under Item 404(a) of Regulation S-K.
In connection with Mr. McMichael’s appointment as Chief Financial Officer, he was granted a stock option award to purchase 75,000 shares of the Company’s common stock, with an exercise price equal to the closing price of the Company’s common stock as reported on the date of grant made pursuant to the Company’s amended and restated 2014 Equity Incentive Award Plan. In connection with the promotion, Mr. McMichael’s base salary was increased to $476,157.06 and his target discretionary bonus threshold was increased to 50% of his base salary.
In connection with his previous appointment as Principal Accounting Officer, the Company entered into an indemnification agreement with Mr. McMichael (the “Indemnification Agreement”) in accordance with the Company’s standard practice and pursuant to the form previously approved by the Company’s board of directors and its stockholders. The Indemnification Agreement, among other things, requires the Company to indemnify Mr. McMichael to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys’ fees, judgments, penalties, fines and settlement amounts incurred by the executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person’s services as an executive officer. The foregoing description of the Indemnification Agreement is a summary of the material terms of such agreement and is qualified in its entirety by reference to the full text of the form of the Indemnification Agreement, which was filed as Exhibit 10.13 to the Company’s Registration Statement on Form S-1/A on October 24, 2014 and is incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 8, 2024 |
| COHERUS BIOSCIENCES, INC. | |
By: | /s/ Dennis M. Lanfear | ||
Name: | Dennis M. Lanfear | ||
Title: | Chief Executive Officer | ||
Exhibit 99.1
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $65.0 million in Q2 2024 –
– CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI –
– Bryan McMichael Appointed as Chief Financial Officer –
– Conference call today at 5:00 p.m. Eastern Time –
REDWOOD CITY, Calif., August 8, 2024 -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2024 and recent business highlights:
RECENT BUSINESS HIGHLIGHTS
UDENYCA® RESULTS
UDENYCA net product sales were $50.9 million in Q2 2024, an increase of 19% compared to $42.7 million in Q1 2024 and a 60% increase compared to $31.7 million in Q2 2023.
| ● | Total unit demand increased 25% in Q2 2024 compared to Q1 2024, and 138% compared to Q2 2023. |
| ● | Based on data from IQVIA, UDENYCA franchise market share for Q2 2024 was 29.0%, an increase of 4 market share points from Q1 2024. |
LOQTORZI® LAUNCH UPDATE
| ● | LOQTORZI, the first and only FDA-approved treatment for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC), commercially launched on January 2, 2024. |
| ● | LOQTORZI net sales in Q2 2024 of $3.8 million, with new patient uptake primarily in relapsed locally advanced and 1L metastatic disease, a potential driver of long-term revenue growth. |
| ● | LOQTORZI can now be ordered in all 33 National Comprehensive Cancer Network (NCCN) institutions. |
| ● | The Centers for Medicare and Medicaid Services granted LOQTORZI a product-specific, permanent J Code, which was implemented on July 1, 2024. |
ADVANCEMENT OF PROMISING IMMUNO-ONCOLOGY PIPELINE
| ● | Clinical data from the dose escalation stage of the Phase 1 study of CHS-114, a highly selective cytolytic anti-CCR8 antibody, was presented at the 2024 ASCO Annual Meeting in June. These data showed selective depletion of peripheral CCR8+ regulatory T cells, establishing proof of mechanism for CHS-114, and an acceptable safety profile with no dose-limiting toxicities, and a disease control rate of 47% in heavily pretreated patients with solid tumors. Expansion cohorts evaluating CHS-114 as monotherapy and in combination with toripalimab are currently enrolling patients with advanced/metastatic head and neck squamous cell carcinoma (HNSCC). |
| ● | A Phase 2 study evaluating casdozokitug, an immune regulatory IL-27 antagonizing antibody, in combination with toripalimab and bevacizumab in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma is expected to begin enrolling patients in Q4 2024. |
| ● | An Investigational New Drug (IND) application for CHS-1000, a novel humanized Fc-modified IgG1 monoclonal antibody specifically targeting ILT4 (LILRB2), was filed with the U.S. Food and Drug Administration (FDA) in Q2 2024 and received clearance. Coherus plans to initiate a Phase 1 study in the coming months. |
“The first half of 2024 has been a period of disciplined execution of our strategy, which included improving our capital structure, advancing our innovative oncology pipeline and driving increasing sales of our commercial portfolio. We continue to streamline our operations, solidifying our focus on our oncology business,” said Denny
1
Lanfear, Coherus’ Chairman and Chief Executive Officer. “Bryan McMichael, our newly appointed Chief Financial Officer, will play a key role on our management team as we further translate this oncology focus into shareholder value.”
"I am honored to carry forward my work at Coherus in the role of Chief Financial Officer. The strength of the team, commercial portfolio, and pipeline gives me great confidence in the Company’s future,” said Bryan McMichael, Coherus’ Chief Financial Officer. “I look forward to continuing in my partnership with Denny, the Board, and other members of management to execute our strategy and bring value to shareholders.”
SECOND QUARTER 2024 FINANCIAL RESULTS
Net revenue was $65.0 million during the three months ended June 30, 2024, and included $50.9 million of net sales of UDENYCA, $3.8 million of net sales of LOQTORZI, which was launched on January 2, 2024, $3.8 million of net sales of YUSIMRY, which was divested to Hong Kong King-Friend Industrial Company Ltd. (“HKF”) on June 26, 2024, and other revenue of $6.5 million which included the $6.3 million up-front cash payment received for the outlicense to Apotex, Inc. of the Canadian rights to LOQTORZI on June 27, 2024. Net revenue was $58.7 million during the three months ended June 30, 2023 and included $26.7 million in revenues for CIMERLI, which was divested on March 1, 2024. Net revenue was $142.0 million and $91.2 million for the six months ended June 30, 2024 and 2023, respectively. Total net revenues attributable to the Company’s divested products, CIMERLI and YUSIMRY, during the first half of 2024 and 2023 were $35.9 million and $32.9 million, respectively.
Cost of goods sold (COGS) was $28.4 million and $24.8 million during the three months ended June 30, 2024 and 2023, respectively, and $63.0 million and $41.7 million during the six months ended June 30, 2024 and 2023, respectively. UDENYCA® COGS included a mid-single digit royalty on net sales which expired on July 1, 2024. The increases in COGS in both 2024 periods were primarily driven by increased unit volumes, and in the second quarter of 2024, a $4.5 million fee for a contract change with a CMO, partially offset by a $9.7 million decrease in royalty costs in the second quarter of 2024, due to the CIMERLI divestiture on March 1, 2024.
Research and development (R&D) expenses were $22.0 million and $23.3 million for the three months ended June 30, 2024 and 2023, respectively, and $50.4 million and $57.4 million for the six months ended June 30, 2024 and 2023, respectively. The decreases were primarily due to savings from reduced headcount and lower costs related to biosimilar products, partially offset by increased costs for development of casdozokitug and CHS-114.
Selling, general and administrative (SG&A) expenses were $35.2 million and $45.1 million during the three months ended June 30, 2024 and 2023, respectively, and $91.7 million and $94.3 million during the six months ended June 30, 2024 and 2023, respectively. The declines in SG&A compared to the prior year periods were driven primarily by lower headcount. The decrease for the six-month period was partially offset by the net $6.8 million charge in the first quarter of 2024 associated with the full write-off of the outlicense intangible asset and associated release of the CVR liability related to NZV930, obtained in the Surface Oncology, Inc. acquisition.
Gain on Sale Transactions, Net which included the divestiture of the YUSIMRY franchise, which closed during the three months ended June 30, 2024, was $22.9 million, and reflects total cash proceeds of $40.0 million, net of assets transferred to HKF, liabilities derecognized, and transactions costs of $0.9 million. Gain on Sale Transactions, net for the first half of 2024 was $177.7 million and included a $154.8 million gain on the divestiture of the CIMERLI franchise, which closed during the three months ended March 31, 2024. There was no gain on Sale Transactions in the first half of 2023.
Interest expense was $5.3 million and $9.9 million during the three months ended June 30, 2024 and 2023, respectively, and $16.5 million and $19.7 million during the six months ended June 30, 2024 and 2023, respectively. The declines in both periods were primarily due to prepaying $175.0 million of the principal amount of the senior secured term loan facility that was entered into on January 5, 2022 on April 1, 2024 and prepaying the remaining $75.0 million principal amount on May 8, 2024. This was offset by interest on the $38.7 million principal amount of the new term loan facility and the revenue participation right purchase and sale agreement, both commencing May 8, 2024, as well as an average higher variable rate in the first half of 2024 compared to the first half of 2023.
2
Net loss for the second quarter of 2024 was $12.9 million, or $(0.11) per share on a diluted basis, compared to a net loss of $42.9 million, or $(0.49) per share on a diluted basis for the same period in 2023. Net income for the first half of 2024 was $90.0 million, or $0.73 per share on a diluted basis, compared to a net loss of $118.6 million, or $(1.42) per share on a diluted basis for the first half of 2023.
Non-GAAP net loss for the second quarter of 2024 was $16.4 million, or $(0.14) per share on a diluted basis, compared to $32.8 million, or $(0.38) per share for the same period in 2023. Non-GAAP net loss for the first half of 2024 was $52.2 million, or $(0.46) per share on a diluted basis, compared to $92.3 million, or $(1.11) per share for the first half of 2023. See “Non-GAAP Financial Measures” below for a discussion on how Coherus calculates non-GAAP net loss and a reconciliation to the most directly comparable GAAP measures.
Cash, cash equivalents and investments in marketable securities were $159.2 million as of June 30, 2024, compared to $117.7 million as of December 31, 2023.
2024 R&D and SG&A Expense Guidance
Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million. This guidance includes approximately $40 million of stock-based compensation expense and excludes the effects of acquisitions, collaborations, investments, divestitures including expenses incurred on behalf of and reimbursed by Sandoz and HKF to satisfy Coherus’ obligations under the transition services agreements with those entities, restructuring, the exercise of rights or options related to collaboration programs, and any other transactions or circumstances not yet identified or quantified. This guidance is subject to a number of risks and uncertainties. See Forward-Looking Statements described in the section below.
Conference Call Information
When: Thursday, August 8, 2024, starting at 5:00 p.m. Eastern Daylight Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI9dd3f986eeb7428485a66ce1fb34999f
Please dial in 15 minutes early to ensure a timely connection to the call.
Webcast: https://edge.media-server.com/mmc/p/kguryzuk
An archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.
About Coherus BioSciences
Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that is expected to be synergistic with its proven commercial capabilities in oncology.
Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. Casdozokitug is a novel anti-IL-27 antibody currently being evaluated in two ongoing clinical studies: a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, ADCC-enhanced anti-CCR8 antibody currently in a Phase 1 study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a novel humanized Fc-modified IgG1 monoclonal antibody specifically targeting ILT4 (LILRB2). An IND application has been accepted by the FDA and Coherus plans to initiate a Phase 1 study in the coming months.
Coherus markets LOQTORZI® (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®.
Neulasta® is a registered trademark of Amgen Inc.
3
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus’ expectations about identifying synergies between its I-O pipeline and its commercial operations; Coherus’ expected timing for the start of a Phase 1 study for CHS-1000; Coherus’ expected timing for enrolling patients in a Phase 2 study evaluating casdozokitug; Coherus’ future projections for R&D and SG&A expenses; and Coherus’ expectations about long term revenue growth.
Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to Coherus’ existing and potential collaboration partners; risks of Coherus’ competitive position; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of Coherus’ regulatory filings; the risk of FDA review issues; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ products and product candidates; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ quarterly filing on Form 10-Q for the fiscal quarter ended June 30, 2024 filed with the Securities and Exchange Commission on or about the date of this press release, including the section therein captioned “Risk Factors” and in other documents Coherus files with the Securities and Exchange Commission. Coherus’ results for the fiscal quarter ended June 30, 2024 are not necessarily indicative of its operating results for any future periods.
UDENYCA®, UDENYCA® ONBODY™, and LOQTORZI®, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners unless otherwise noted. Trademarks and trade names of other companies appearing in this press release are, to the knowledge of Coherus, the property of their respective owners.
Coherus Contact Information:
For Investors:
Jami Taylor
Head of Investor Relations
IR@coherus.com
For Media:
Jodi Sievers
VP, Corporate Communications
media@coherus.com
4
Coherus BioSciences, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
| | Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | June 30, | ||||||||
|
| 2024 |
| 2023 |
| 2024 |
| 2023 | ||||
Net revenue | | $ | 64,979 | | $ | 58,716 | | $ | 142,042 | | $ | 91,152 |
Costs and expenses: | |
| | |
| | |
| | |
| |
Cost of goods sold | |
| 28,368 | |
| 24,848 | |
| 62,954 | |
| 41,722 |
Research and development | |
| 21,955 | |
| 23,267 | |
| 50,425 | |
| 57,421 |
Selling, general and administrative | |
| 35,165 | |
| 45,144 | |
| 91,697 | |
| 94,297 |
Total costs and expenses | |
| 85,488 | |
| 93,259 | |
| 205,076 | |
| 193,440 |
Loss from operations | |
| (20,509) | |
| (34,543) | |
| (63,034) | | | (102,288) |
Interest expense | |
| (5,334) | |
| (9,943) | |
| (16,450) | |
| (19,655) |
Gain on Sale Transactions, net | | | 24,085 | | | — | | | 177,732 | | | — |
Loss on debt extinguishment | | | (12,630) | | | — | | | (12,630) | | | — |
Other income (expense), net | |
| 1,467 | |
| 1,617 | |
| 4,336 | |
| 3,345 |
Income (loss) before income taxes | |
| (12,921) | |
| (42,869) | |
| 89,954 | |
| (118,598) |
Income tax provision | |
| — | |
| — | |
| — | |
| — |
Net income (loss) | | $ | (12,921) | | $ | (42,869) | | $ | 89,954 | | $ | (118,598) |
| |
|
| |
|
| |
|
| |
|
|
Net income (loss) per share: | | | | | | | | | | | | |
Basic | | $ | (0.11) | | $ | (0.49) | | $ | 0.79 | | $ | (1.42) |
Diluted | | $ | (0.11) | | $ | (0.49) | | $ | 0.73 | | $ | (1.42) |
| | | | | | | | | | | | |
Weighted-average number of shares used in computing net income (loss) per share: | |
| | | | | |
| | | | |
Basic | | | 114,819,965 | | | 87,269,614 | | | 113,784,636 | | | 83,469,247 |
Diluted | | | 114,819,965 | |
| 87,269,614 | |
| 126,174,802 | |
| 83,469,247 |
5
Coherus BioSciences, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| | June 30, | | December 31, | ||
|
| 2024 |
| 2023 | ||
Assets |
| |
|
| |
|
Cash and cash equivalents |
| $ | 159,240 | | $ | 102,891 |
Investments in marketable securities | | | — | | | 14,857 |
Trade receivables, net | | | 175,251 | | | 260,522 |
TSA receivables, net | | | 138,317 | | | — |
Inventory | | | 112,041 | |
| 130,100 |
Intangible assets, net | | | 55,455 | | | 71,673 |
Other assets | |
| 34,551 | |
| 49,561 |
Total assets | | $ | 674,855 | | $ | 629,604 |
| | | | | | |
Liabilities and Stockholders’ Deficit | |
| | |
| |
Accrued rebates, fees and reserve | | $ | 177,455 | | $ | 169,645 |
TSA payables and other accrued liabilities | | | 133,536 | | | — |
Term loans | | | 36,541 | | | 246,481 |
Convertible notes | | | 227,555 | | | 226,888 |
Other liabilities | |
| 183,876 | |
| 180,015 |
Total stockholders' deficit | |
| (84,108) | | | (193,425) |
Total liabilities and stockholders’ deficit | | $ | 674,855 | | $ | 629,604 |
6
Coherus BioSciences, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
| | Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | June 30, | ||||||||
|
| 2024 |
| 2023 |
| 2024 |
| 2023 | ||||
Cash, cash equivalents and restricted cash at beginning of the period | | $ | 260,227 | | $ | 16,585 | | $ | 103,343 | | $ | 63,987 |
| |
| | |
| | |
| | |
| |
Net cash provided by (used in) operating activities | |
| 59,734 | |
| (38,915) | |
| 12,968 | |
| (107,647) |
| |
| | |
| | |
| | |
| |
Proceeds from maturities of investments in marketable securities | | | — | | | 47,250 | | | 6,200 | | | 64,750 |
Proceeds from sale of investments in marketable securities | | | — | | | 13,282 | | | 8,688 | | | 13,282 |
Cash received from CIMERLI sale | | | — | | | — | | | 187,823 | | | — |
Cash received from YUSIMRY sale | | | 40,000 | | | — | | | 40,000 | | | — |
Milestone based license fee payment to Junshi Biosciences | | | (12,500) | | | — | | | (12,500) | | | — |
Purchases of investments in marketable securities | |
| — | |
| (19,507) | |
| — | |
| (19,507) |
Other investing activities, net | |
| 156 | |
| 340 | |
| 208 | |
| 366 |
Net cash provided by investing activities | |
| 27,656 | |
| 41,365 | |
| 230,419 | |
| 58,891 |
| |
| | |
| | |
| | |
| |
Proceeds from 2029 Term Loan, net of debt discount & issuance costs | | | 37,120 | | | — | | | 37,120 | | | — |
Proceeds from Revenue Purchase and Sale Agreement, net of issuance costs | | | 36,495 | | | — | | | 36,495 | | | — |
Proceeds from issuance of common stock under ATM Offering, net of issuance costs | | | (52) | | | (74) | | | 1,455 | | | 6,761 |
Proceeds from issuance of common stock under Public Offering, net of issuance costs | | | — | | | 53,625 | | | — | | | 53,625 |
Proceeds from issuance of common stock upon exercise of stock options | | | — | | | 14 | | | 291 | | | 117 |
Proceeds from purchase under the employee stock purchase plan | | | 685 | | | 1,337 | | | 685 | | | 1,337 |
Repayment of 2027 Term Loans, premiums and fees | | | (260,387) | | | — | | | (260,387) | | | — |
Taxes paid related to net share settlement | | | (1,711) | | | (305) | | | (2,456) | | | (3,086) |
Other financing activities | | | (75) | | | (272) | | | (241) | | | (625) |
Net cash (used in) provided by financing activities | |
| (187,925) | |
| 54,325 | |
| (187,038) | |
| 58,129 |
| |
| | |
| | |
| | |
| |
Net increase (decrease) in cash, cash equivalents and restricted cash | |
| (100,535) | |
| 56,775 | |
| 56,349 | |
| 9,373 |
| | | | | | | | | | | | |
Cash, cash equivalents and restricted cash at end of the period | | $ | 159,692 | | $ | 73,360 | | $ | 159,692 | | $ | 73,360 |
| | | | | | | | | | | | |
Reconciliation of cash, cash equivalents, and restricted cash | | | | | | | | | | | | |
Cash and cash equivalents | | $ | 159,240 | | $ | 72,920 | | $ | 159,240 | | $ | 72,920 |
Restricted cash balance | | | 452 | | | 440 | | | 452 | | | 440 |
Cash, cash equivalents and restricted cash | | $ | 159,692 | | $ | 73,360 | | $ | 159,692 | | $ | 73,360 |
7
Non-GAAP Financial Measures
To supplement the financial results presented in accordance with GAAP, Coherus has also included in this press release non-GAAP net loss, and the related per share measures, which exclude from net income (loss), and the related per share measures, stock-based compensation expense, certain acquisition-related expenses, amortization of intangible assets, gain on divestiture, impairments of intangible assets, contingent consideration, loss on debt extinguishment and restructuring charges related to our reduction in workforce. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. Coherus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand Coherus’ business.
Coherus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, Coherus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Coherus’ results from period to period, and to identify operating trends in Coherus’ business. Coherus also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.
Coherus BioSciences, Inc.
Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Loss
(in thousands, except share and per share data)
(unaudited)
| | Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | June 30, | ||||||||
|
| 2024 |
| 2023 |
| 2024 |
| 2023 | ||||
GAAP net income (loss) | | $ | (12,921) | | $ | (42,869) | | $ | 89,954 | | $ | (118,598) |
Adjustments: | | | | | | | | | | | | |
Stock-based compensation expense(1) | | | 7,231 | | | 10,077 | | | 14,550 | | | 21,410 |
Gain on Sale Transactions, net | | | (24,085) | | | — | | | (177,732) | | | — |
Loss on debt extinguishment | | | 12,630 | | | — | | | 12,630 | | | — |
Impairment of out-license asset and remeasurement of CVR liability, net | | | — | | | — | | | 6,772 | | | — |
Restructuring charges related to reduction in workforce(1) | | | — | | | — | | | — | | | 4,876 |
Amortization of intangible assets | | | 704 | | | — | | | 1,634 | | | — |
Non-GAAP net loss | | $ | (16,441) | | $ | (32,792) | | $ | (52,192) | | $ | (92,312) |
| | | | | | | | | | | | |
GAAP | | | | | | | | | | | | |
Net income (loss) per share, basic | | $ | (0.11) | | $ | (0.49) | | $ | 0.79 | | $ | (1.42) |
Net income (loss) per share, diluted | | $ | (0.11) | | $ | (0.49) | | $ | 0.73 | | $ | (1.42) |
Shares used in computing basic net income (loss) per share | | | 114,819,965 | | | 87,269,614 | | | 113,784,636 | | | 83,469,247 |
Shares used in computing diluted net income (loss) per share | | | 114,819,965 | | | 87,269,614 | | | 126,174,802 | | | 83,469,247 |
| | | | | | | | | | | | |
Non-GAAP | | | | | | | | | | | | |
Net loss per share, basic and diluted | | $ | (0.14) | | $ | (0.38) | | $ | (0.46) | | $ | (1.11) |
Shares used in computing basic and diluted net loss per share | | | 114,819,965 | | | 87,269,614 | | | 113,784,636 | | | 83,469,247 |
| (1) | In the six months ended June 30, 2023, stock-based compensation of $1.0 million was classified within Restructuring charges related to reduction in workforce. |
8